73 results on '"Wirth, Lori J."'
Search Results
2. Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy.
3. Impact of tertiary lymphoid structures in response to immune checkpoint blockade in patients with head and neck squamous cell carcinoma.
4. Multi-feature next-generation liquid biopsy for diagnosis and prognosis in HPV-associated head and neck cancer.
5. Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
6. Cabozantinib in Progressive Medullary Thyroid Cancer
7. A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.
8. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
9. A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).
10. Improved laryngeal function after neoadjuvant therapy for advanced thyroid cancer: A potential outcome of interest for future clinical trials.
11. Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy.
12. Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
13. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
14. Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
15. NTRK, RET, BRAF, and ALK fusions in thyroid fine-needle aspirates (FNAs).
16. Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.
17. Patient-reported outcomes (PROs) from a phase II trial of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal and/or pulmonary involvement.
18. PD-1 Blockade in Anaplastic Thyroid Carcinoma
19. Immune functional portraits of head and neck cancer using next generation sequencing.
20. Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
21. Immune checkpoint inhibitor in nasopharyngeal carcinoma: Multi-institution experience.
22. Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
23. Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
24. Genomic landscape of FNAs positive for medullary thyroid cancer (MTC) and potential impact on systemic therapy.
25. A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and/or pulmonary involvement.
26. Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).
27. A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.
28. ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notchact mut).
29. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
30. Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.
31. Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.
32. ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine.
33. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
34. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
35. IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC.
36. Effect of cabozantinib on bone turnover markers (BTM) and bone metastases (BM) in radioiodine refractory (RAIR)-differentiated thyroid cancer (DTC).
37. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
38. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
39. A two-group study to evaluate the impact of an educational handbook in the care of patients with head and neck cancer (HNC).
40. Patient reported outcomes (PROs) in patients with human papilloma virus (HPV) positive versus negative head and neck cancer (HNC).
41. Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).
42. Cetuximab in Human Papillomavirus–Positive Oropharynx Carcinoma
43. First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET -altered solid tumors.
44. Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT.
45. Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.
46. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).
47. Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.
48. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC).
49. Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
50. Neoadjuvant erlotinib, erlotinib-sulindac, or placebo: A randomized, double-blind biomarker modulation study in operable head and neck squamous cell carcinoma (HNSCC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.